Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001193125-26-054764·ADC Therapeutics SA
Schedule 13G ownership disclosure
ADC THERAPEUTICS SA
Common Shares, par value CHF $0.08 per share · CUSIP: H0036K147
Event date: 2025-10-27
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TCG Crossover GP II, LLC
Shares: 11,390,175 · Class: 9.2%
- TCG Crossover Fund II, L.P.
Shares: 11,390,175 · Class: 9.2%
- Chen Yu
Shares: 11,390,175 · Class: 9.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-054764
- Form type
- SCHEDULE 13G
- Filer
- ADC Therapeutics SA
- CIK
- CIK 1771910
- Filed
- Feb 17, 2026
- Reporting period
- Oct 27, 2025
- Description
- Schedule 13G beneficial ownership